Drug Profile
Research programme: pyrimidinedione analogues - ImQuest/Samjin
Alternative Names: IQP-0568; IQP-0589; IQP-1187; Second-generation pyrimidinediones - ImQuest/SamjinLatest Information Update: 28 Jul 2020
Price :
$50
*
At a glance
- Originator Samjin Pharmaceutical Company
- Developer ImQuest Life Sciences; University of Utah
- Class Pyrimidinones; Small molecules
- Mechanism of Action Hepatitis C virus replication inhibitors; RNA-directed DNA polymerase inhibitors; Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatitis B; Hepatitis C; HIV infections
Most Recent Events
- 20 Jul 2020 ImQuest Life Sciences has been acquired by Cytocom
- 04 Nov 2017 No recent reports of development identified for preclinical development in Hepatitis-B in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Hepatitis-C in USA